![Tina Albertson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tina Albertson
Technik-/Wissenschafts-/F&E-Leiter bei
CARIBOU BIOSCIENCES, INC.
Vermögen: 161 714 $ am 31.05.2026
Profil
Tina Albertson currently works at Caribou Biosciences, Inc., as Chief Medical Officer from 2024.
Dr. Albertson also formerly worked at Seagen, Inc., as Medical Director from 2010 to 2015, Juno Therapeutics, Inc., as Vice President-Global Drug Development from 2015 to 2020, and Lyell Immunopharma, Inc., as Chief Medical Officer & Head-Development from 2020 to 2023.
Dr. Albertson received her doctorate degree from Stanford University, doctorate degree from the University of Washington, and undergraduate degree from the University of Oregon.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 24.02.2026 | 68 523 ( 0,07 % ) | 161 714 $ | 31.05.2026 |
Aktive Positionen von Tina Albertson
| Unternehmen | Position | Beginn |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 12.08.2024 |
Ehemalige bekannte Positionen von Tina Albertson
| Unternehmen | Position | Ende |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2023 |
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01.04.2020 |
| SEAGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2015 |
Ausbildung von Tina Albertson
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
42
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Seagen, Inc.
 Seagen, Inc. Pharmaceuticals: MajorHealth Technology Develops monoclonal antibody-based therapeutic products for treatment of cancer and immunologic diseases | Health Technology |
Caribou Biosciences, Inc.
 Caribou Biosciences, Inc. BiotechnologyHealth Technology Develops technology-based solutions for cellular engineering and analysis | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oregon
 University of Oregon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company to treat cancer, HIV and cardiovascular diseases | Health Technology |
Lyell Immunopharma, Inc.
 Lyell Immunopharma, Inc. BiotechnologyHealth Technology Develops cell-based immunotherapies for human diseases | Health Technology |
